Latest news with #CMPS
Yahoo
7 days ago
- Business
- Yahoo
Compass Pathways price target lowered to $40 from $45 at H.C. Wainwright
H.C. Wainwright lowered the firm's price target on Compass Pathways (CMPS) to $40 from $45 and keeps a Buy rating on the shares. Compass confirmed that no further development is planned in anorexia nervosa following completion of the Phase 2 trial, the analyst tells investors in a research note. As such, the firm removed the indication from its model post the Q2 report. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on CMPS: Disclaimer & DisclosureReport an Issue Compass Pathways' Phase III Study on COMP360: A Potential Breakthrough in Treating Depression Compass Pathways Reports Strong Progress in Q2 2025 Compass Pathways' Earnings Call Highlights Success and Challenges Positive Buy Rating for COMPASS Pathways Driven by Strategic Progress and Financial Stability Compass Pathways' Phase III Study on COMP360: A Potential Game-Changer in Depression Treatment Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-06-2025
- Business
- Yahoo
This Psychedelic Drug Flopped on Trial Results. Should You Buy the Dip?
Psychedelic stocks are gaining attention as new ways to treat mental illnesses like depression and post-traumatic stress disorder (PTSD). Companies in the niche use substances like psilocybin to develop treatments that present alternatives to traditional pharmaceutical compounds. Investors are hopeful, but the road to approval is risky and drawn out. Compass Pathways (CMPS) just faced one of those setbacks when it ran a late‐stage (Phase 3) trial of its synthetic psilocybin drug (COMP360) in 258 adults with treatment-resistant depression. Those receiving the treatment had a 3.6-point greater reduction in symptoms versus those receiving the placebo, which met the trial's predefined goal of at least a 3-point difference, but came up short of the 5-point gap Wall Street had hoped for. As a result, shares plunged nearly 50% on Monday, June 23. Analysts: AMD Stock Will 'Close the Gap' With Nvidia by 2026. Should You Buy AMD Stock Here? The Saturday Spread: Data-Driven Trades That Cut Through the Noise (GILD, MCD, DJT) Why This Wildcard Stock Could Be a Future Star Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Despite the drop, analysts remain mostly bullish. The company has another major trial underway, with results expected next year. If that data is stronger, the stock could rebound sharply. Compass is also pushing ahead in studies for PTSD. For investors who believe in the future of mental health innovation, this dip might be an opportunity to get in at a better price. Based in London, Compass Pathways is a biotechnology company focused on developing innovative treatments for mental health conditions, primarily targeting psilocybin for treatment-resistant depression (TRD). Valued at $248 million in market cap, shares of this psychedelic drug company have plunged 54% over the past 52 weeks and are down 27% year to date, significantly underperforming the broader S&P 500 Index ($SPX). After the haircut, CMPS is more attractively valued with a price-book ratio of 1.31x, significantly cheaper than the sector median of 2.7x. This pricing suggests CMPS may offer a good entry point relative to its peers. While COMP360 met its goal in the COMP005 trial, the modest 3.6-point improvement disappointed markets, causing a sharp stock correction. Still, Compass Pathways is gearing up for a key catalyst in 2026, its 26-week readout from two Phase 3 trials testing its psilocybin-based treatment for treatment-resistant depression (TRD). While earlier data showed promising six- and twelve-week effects, investors remain cautious about long-term durability and patient variability. Some fear the treatment may be too niche or selective, especially with reports of adverse events in prior trials. Still, if the results are positive, Compass could gain serious momentum toward FDA approval. Compass Pathways appears to be on stable financial footing as it advances its clinical programs. In Q1 2025, the company reported $260.1 million in cash and cash equivalents. This capital base was secured through a combination of financing mechanisms, including a private investment in public equity (PIPE) deal, a loan agreement with Hercules Capital, and an established at-the-market (ATM) offering program. With a current quarterly cash burn of approximately $49.6 million, comprising $30.9 million in research and development expenses and $18.7 million in general and administrative costs, Compass projects that its existing cash reserves will support operations through the second half of 2026. This timeline aligns with the anticipated data release from its ongoing Phase 3 COMP006 trial. Wall Street analysts remain confident about the company's future growth prospects, as reflected in their consensus 'Strong Buy' rating. Among the 10 analysts covering the stock, eight rate it a 'Strong Buy,' one gives a 'Moderate Buy,' and one rates it a 'Hold.' The 12-month average price target is $16.40, implying upside potential of 483% from current levels. Compass Pathways is still a high-risk bet, with regulatory hurdles and clinical uncertainty ahead. But for investors who believe in the future of psychedelic medicine, this dip could be an attractive entry. While caution is warranted, the upside remains compelling for those with a long-term view. On the date of publication, Nauman Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Express Tribune
03-06-2025
- Politics
- Express Tribune
Trump Proposes $1B for Private Sector to Lead Mars Exploration in NASA Budget
President Donald Trump has laid out an ambitious proposal in his 2026 budget that allocates $1 billion for Mars exploration. Under the initiative, dubbed the Commercial Mars Payload Services Program (CMPS), NASA would collaborate with private companies to develop key technologies for Mars missions. The proposal includes contracts for spacesuits, communication systems, and a human-rated landing vehicle. The plan marks a shift from traditional government-led space exploration, aligning closely with SpaceX's ambitions for Mars, as spearheaded by Elon Musk. The budget suggests a significant reduction in NASA's funding, including cuts to its science portfolio, with Trump emphasizing cost efficiency and the need for taxpayer stewardship. Critics of the plan, including lawmakers and former NASA officials, argue that the proposed cuts could hinder long-term goals. Despite this, the administration remains confident that the private sector can play a crucial role in achieving Mars exploration while reducing costs and risks. This bold proposal sets the stage for a new era of space exploration that blends government oversight with private sector innovation. President Trump said it himself: We're going to lead humanity into space and plant the American flag on MARS! — Rep. Mike Haridopolos (@RepHaridopolos) March 5, 2025
Deccan Herald
31-05-2025
- Business
- Deccan Herald
Trump wants $1 billion for private-sector-led Mars exploration
The White House's 2026 budget proposal, released late on Friday, calls for allocating more than $1 billion for Mars exploration, including a new NASA initiative called the Commercial Mars Payload Services Program (CMPS).
&w=3840&q=100)
Business Standard
31-05-2025
- Business
- Business Standard
Trump seeks $1 billion for private-sector-led human missions to Mars
The White House's 2026 budget proposal, calls for allocating more than $1 billion for Mars exploration, including a new Nasa initiative called the Commercial Mars Payload Services programme Bloomberg US President Donald Trump wants to tap the private sector to pave the way for human missions to Mars in a proposal that closely aligns with the goals of Elon Musk. The White House's 2026 budget proposal, released late on Friday, calls for allocating more than $1 billion for Mars exploration, including a new Nasa initiative called the Commercial Mars Payload Services Programme (CMPS). Under the proposal, Nasa would award contracts to companies developing spacesuits, communications systems and a human-rated landing vehicle to foster exploration of the Red Planet. Trump's proposed $18.8 billion Nasa budget would cut the agency's funding by about 25 per cent from the year before, with big hits to its science portfolio. The fleshed-out request on Friday builds upon a condensed budget proposal released earlier this month. 'We must continue to be responsible stewards of taxpayer dollars,' Nasa Acting Administrator Janet Petro wrote in a letter included in the request. 'That means making strategic decisions — including scaling back or discontinuing ineffective efforts.' According to the budget, the contract to land on Mars would build upon existing lander contracts. Musk's SpaceX is already developing a version of its Starship rocket to take Americans back to the moon's surface under the agency's Artemis program. Musk laid out a grandiose vision for a sprawling settlement on Mars during a talk earlier this week with SpaceX employees. Trump's pick to run Nasa, tech billionaire Jared Isaacman, told lawmakers the agency could pursue the moon and Mars in parallel. The administration's proposed cuts, particularly changes to Nasa's science portfolio, have generated criticism from people in the space industry and lawmakers, including from former Republican Congressmen like Newt Gingrich and Bob Walker. Isaacman himself said the science cuts wouldn't be an 'optimal outcome.' The administration earlier revealed plans to phase out the Boeing Co.-built Space Launch System rocket and the Lockheed Martin Corp. Orion crew capsule, parts of which have been in development for years, after three flights. Instead, the budget details a strategy for new, private sector-led trips back to the moon, which the White House said would minimize costs and reduce schedule risks. It would be modeled on a Nasa program that helped to fuel development of SpaceX's Falcon 9 rocket and Northrop Grumman Corp.'s cargo-hauling Cygnus. The budget proposal is likely to run into resistance from veteran members of Congress, like Texas Republicans Senator Ted Cruz and Representative Brian Babin, who have fiercely defended the current plans for going back to the moon.
